Aurora Spine (ASG) AI Stock Analysis

• Market Cap: C$24.20M
• Dividend Yield: N/A
• Average Volume (3M): 39.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: 18.97%
• EPS Growth: 17.57%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 78,054,950
• 10 Day Avg. Volume: 12,060
• 30 Day Avg. Volume: 39,691
• PEG Ratio: 0.34
• Price to Book (P/B): 5.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.22
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 0.38
• Enterprise Value/Gross Profit: 2.35
• Enterprise Value/Ebitda: 28.75
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: C$0.50 ▲(61.29%Upside)

Aurora Spine has shown commendable revenue growth and cash flow improvements, but profitability remains a concern. The stock's technical indicators suggest weak momentum, and valuation is affected by negative earnings. Positive corporate events and product successes provide strategic growth potential, yet the financial challenges need addressing to enhance the overall outlook.

Aurora Spine Business Overview & Revenue Model

Company Description

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality. Aurora Spine Corporation was incorporated in 2013 and is headquartered in Toronto, Canada.

How the Company Makes Money

Aurora Spine makes money through the sale of its medical device products to hospitals, surgical centers, and healthcare providers. The company's revenue model relies on the direct sales of its spinal fusion devices, proprietary surgical tools, and pain management products. Additionally, Aurora Spine may engage in strategic partnerships with healthcare institutions and distributors to expand its market reach and enhance product distribution. The company invests in research and development to continuously innovate and meet the evolving needs of the spinal surgery market, thereby potentially increasing its revenue streams.

Aurora Spine Financial Statement Overview

Summary

Aurora Spine shows solid revenue growth and improved cash flow management. However, the company continues to face profitability challenges with ongoing net losses and negative EBIT margins. The balance sheet indicates manageable leverage but a declining equity ratio.

Income Statement

Aurora Spine has shown a commendable improvement in revenue growth, with a 20.94% increase in 2024. Despite this growth, the company is still facing profitability challenges, as indicated by negative EBIT and net income margins. Gross profit margin stands at 60.55%, demonstrating efficient cost management. However, consistent losses over the years highlight the need for strategic adjustments to enhance profitability.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.83 in 2024, indicating manageable leverage. However, the equity ratio has decreased to 37.68%, showing reduced equity financing. Return on equity remains negative due to continuing losses, suggesting a need for improved operational efficiency to enhance shareholder value.

Cash Flow

Aurora Spine's cash flow has improved significantly, with a positive operating cash flow of $904,332 in 2024, compared to negative flows in previous years. Free cash flow has turned positive at $266,471, indicating better cash management. The operating cash flow to net income ratio is strong, reflecting efficient cash generation relative to net losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
17.56M	14.52M	14.88M	10.54M	8.65M
	Gross Profit
10.63M	8.21M	7.81M	4.83M	3.47M
	EBIT
-673.98K	-446.20K	-1.57M	-2.71M	-1.25M
	EBITDA
179.90K	-446.20K	-469.27K	-1.90M	-573.86K
	Net Income Common Stockholders
-1.00M	-1.68M	-1.50M	-2.36M	-232.09K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
775.62K	766.83K	423.40K	3.17M	1.71M
	Total Assets
11.67M	11.99M	10.12M	10.56M	7.16M
	Total Debt
3.67M	3.65M	2.97M	2.38M	2.34M
	Net Debt
2.90M	2.88M	2.55M	-627.41K	632.23K
	Total Liabilities
7.28M	6.69M	5.81M	4.99M	3.87M
	Stockholders Equity
4.40M	5.30M	4.32M	5.57M	3.28M
Cash Flow		Free Cash Flow
266.47K	-1.41M	-2.43M	-2.85M	-245.07K
	Operating Cash Flow
904.33K	-935.06K	-1.56M	-2.13M	309.57K
	Investing Cash Flow
-484.32K	-479.13K	-873.21K	-720.61K	-554.64K
	Financing Cash Flow
-361.22K	1.76M	-318.15K	4.31M	1.51M

Aurora Spine Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.32, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.86 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASG.

Aurora Spine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	65 Neutral	C$121.64M	―	-8.34%	―	0.69%	-95.27%
ASG	62 Neutral	C$24.20M	―	-23.87%	―	18.97%	17.57%
PRN	54 Neutral	C$256.05M	―	-66.14%	―	51.21%	15.33%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
PINK	50 Neutral	C$21.51M	―	-163.62%	―	113.85%	11.38%
TLT	44 Neutral	C$45.15M	―	-291.48%	―	-8.63%	7.04%
VPT	44 Neutral	C$17.97M	―	207.08%	―	280.56%	-7.28%

Aurora Spine Corporate Events

Aurora Spine Achieves Milestone with SiLO™ System in Over 2,500 Procedures

Aurora Spine has achieved a significant milestone with its SiLO™ Sacroiliac Joint Fusion System, which has been used in over 2,500 procedures across the United States. This accomplishment highlights the growing adoption of their minimally invasive technology, which is designed to improve patient outcomes and recovery times. The company’s continued innovation and expansion in the U.S. market, along with positive feedback from the surgical community, underscore its leadership in the field of spinal solutions.

Aurora Spine to Engage Investors at Lytham Partners Spring 2025 Conference

Aurora Spine Corporation announced its participation in the Lytham Partners Spring 2025 Investor Conference, where it will present a webcast and host one-on-one meetings with investors. This participation underscores Aurora Spine’s commitment to engaging with investors and stakeholders, potentially enhancing its market presence and investor relations.

Aurora Spine Reports Record Q1 2025 Financial Results and Strategic Growth Initiatives

Aurora Spine Corporation announced record financial results for the first quarter of 2025, with a 10% increase in revenue compared to the previous year. The company received FDA clearance for its AERO Facet Fusion System and reported significant sales growth in its DEXA-C cervical implant. Aurora Spine is optimistic about future growth, driven by its robust R&D efforts and upcoming product launches, including the DEXA-L series and the AERO system, which are expected to enhance patient outcomes and expand market reach.

Aurora Spine to Announce Q1 2025 Financial Results

Aurora Spine Corporation announced the release schedule for its first quarter fiscal 2025 financial results, which will be filed on May 21, 2025, with a press release and investor conference call to follow on May 22, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

Aurora Spine Reports Record Revenue and Positive EBITDAC for FY 2024

Aurora Spine Corporation reported a record revenue of $17.6 million for fiscal year 2024, marking a 21% increase from the previous year. The company’s financial success was driven by a 135% surge in sales of the SiLO-TFX SI joint implant, expansion of its internal sales force, and increased margins. The company also achieved its first annual positive EBITDAC and is poised for further growth with the recent FDA clearance of its new AERO product platform.

Aurora Spine to Release Q4 and Fiscal 2024 Financial Results

Aurora Spine Corporation announced the release of its fourth quarter and fiscal year 2024 financial results, scheduled for April 28, 2025. The company also clarified an error in its management information circulars regarding its stock option plan, ensuring the correct version will be included in future shareholder meeting materials.

Aurora Spine Board Member James Snow Resigns to Assume Key Operational Role

Aurora Spine has announced the resignation of James Snow from its Board of Directors as he transitions to the role of Regulatory Affairs and Quality Assurance Manager within the company. This move highlights Snow’s commitment to Aurora Spine’s future and his belief in the company’s innovative technologies, as he aims to enhance compliance and quality across their product portfolio.

Aurora Spine’s SiLO TFX System Shows Superior Performance in New Study

Aurora Spine announced the publication of a biomechanical study in the journal Neurospine, demonstrating the superior performance of its SiLO TFX ™ Sacroiliac Fusion System compared to traditional methods. The study highlights the system’s ability to reduce joint motion and preserve bone integrity, offering a promising alternative for sacroiliac joint fusion. The findings support Aurora Spine’s commitment to optimizing patient outcomes and reinforce its position as a leader in spinal implant technology.

Aurora Spine Secures FDA Clearance for AERO Facet Fusion System

Aurora Spine has received FDA 510(k) clearance for its AERO Facet Fusion System, a minimally invasive device designed for patients with facet joint-related pain or instability. The system, which can be used independently or alongside larger spinal fusion surgeries, is expected to begin initial surgeries in late Q3 2025. The AERO system is engineered to promote bone fusion while minimizing soft tissue disruption, aligning with Aurora Spine’s commitment to patient-first innovations. The clearance is seen as a significant milestone for the company, with expectations that the AERO system will drive growth and improve patient care in spinal surgery.